Fairmount Partners Advises Accugenix on Sale to Charles River Laboratories

Fairmount Partners Advises Accugenix in Sale to Charles River Laboratories

NEWARK, DE – August 24, 2012 – Accugenix, the global leader in cGMP compliant microbial identification testing, has been acquired by Charles River Laboratories (NYSE: CRL), a provider of essential products and contract services to that advance drug discovery and development.

Headquartered in the U.S. with an office in Germany, Accugenix has established itself as the world’s leading FDA registered, cGMP compliant contract microbial testing service laboratory over the past 20 years, specializing in bacterial and fungal identification and strain typing of environmental isolates. Predominantly serving the biotechnology and pharmaceutical industries, but also consumer products and food processors, Accugenix has identified microorganisms from samples collected from over 1,000 sterile facilities worldwide. The Company has assembled proprietary libraries which allow it to quickly, efficiently and accurately identify over 5,000 species of organisms.

Accugenix was lead by CEO Doug Smith, a pioneer in development and commercialization of automated microbial identification systems, including the MicroSEQ® system, and leading developer of systems and scientific equipment for Applied BioSystems, Agilent/Hewlett Packard, Spectra Physics, and Genomyx/Genentech, and COO Patty Wray, an industry veteran from LabCorp, Monogram Biosciences, Genentech and Hewlett-Packard, who oversaw the recent expansion and growth of the business.

James C. Foster, chairman, president and chief executive officer of Charles River, said, “The acquisition of Accugenix is the first step in our broader strategy to become the premier provider of rapid microbial and endotoxin detection products and services to the biopharmaceutical industry. Over the next several years, we intend to enhance our capabilities through both product extensions and acquisitions. We believe that execution of this strategy will advance our position as the market leader in endotoxin and microbial detection.”

Fairmount Partners, a specialty investment bank based outside Philadelphia, Pennsylvania, advised Accugenix. Neal McCarthy, Managing Director of Fairmount Partners, added, “With the support, resources and global network of Charles River behind them, Accugenix is poised to expand its global footprint as the best lab in microbial identification services.”

About Fairmount Partners

Fairmount Partners is one of the largest investment banking groups in the Mid-Atlantic region. The firm specializes in advising middle-market growth companies with mergers and acquisitions, capital raising and strategic advice. Fairmount’s key focus areas include: Healthcare, IT and Business Services, Software & Technology and Industrial & Consumer businesses. Fairmount has completed transactions throughout North and South America, Europe and Asia. For more information, visit: www.fairmountpartners.com.

Principals of Fairmount Partners acted as advisors to Accugenix in this transaction.

Contact

Neal McCarthy

Managing Director, Fairmount Partners

neal.mccarthy@fairmountpartners.com